Novavax to Make Multiple Presentations at RSV Vaccines for the World
November 16 2015 - 4:05PM
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company
focused on the discovery, development and commercialization of
recombinant nanoparticle vaccines and adjuvants, today announced
that Novavax representatives will be making multiple oral
presentations at the RSV Vaccines for the World conference,
November 18-20, 2015 in La Jolla, California.
Poster, presentation titles and presenters are
listed below:
- “Biophysical Characterization of an RSV Nanoparticle
Vaccine.”Oleg Borisov, Ph.D., Director, Analytical Development,
Novavax, Inc.
- “Randomized Phase 2 Trial of an RSV F Nanoparticle Vaccine in
the Elderly: Epidemiology and Efficacy.”Vivek Shinde, M.D.,
Director, Clinical Development, Novavax, Inc.
- “Phase 2 Trial of an RSV F Nanoparticle Vaccine in Pregnant
Women Towards Maternal Immunization.”Allison August, M.D.,
Director, Clinical Research, Novavax, Inc.
- “Sera Derived from Immunization with a Recombinant RSV
F-protein Nanoparticle Vaccine Obtained from Cotton Rats and Women
of Child-bearing Age Contains Antibodies Competitive with
Neutralizing Monoclonals Against Multiple Epitopes.”Hanxin Lu,
Ph.D., Senior Scientist, Novavax, Inc.
The final conference program is available at:
http://www.meetingsmanagement.co.uk/images/stories/pdf/rsvvw-2015-leaflet.pdf
About RSV
RSV is a major respiratory pathogen in infants,
children, and adults. RSV infections in adults represent
re-infections and are generally mild to moderate in severity,
except in persons with high-risk conditions including the elderly
and adults with underlying chronic cardiac or pulmonary disease. It
is estimated that 2.4 million adults 65 years of age or older are
infected with RSV annually in the U.S. leading to as many as
900,000 medical interventions and 14,000 deaths each year.1-5 RSV
is the most common cause of lower respiratory tract infections and
the leading viral cause of severe lower respiratory tract disease
in infants and young children worldwide, with estimated annual
infection and mortality rates of 64 million and 160,000,
respectively.6 In the US, RSV is the leading cause of
hospitalization of infants.7 Currently, there is no approved
RSV vaccine available.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
vaccine company committed to delivering novel products to prevent a
broad range of infectious diseases. Our recombinant nanoparticles
and Matrix-M™ adjuvant technology are the foundation for
groundbreaking innovation that improves global health through safe
and effective vaccines. Additional information about Novavax is
available on the Company's website, novavax.com.
References:
- Falsey, A.R. et al. Respiratory syncytial virus
infection in elderly and high-risk adults. N Engl J Med, 2005;
352:1749–59; extrapolated to 2015 census population.
- Falsey, A.R. et al. Respiratory Syncytial Virus and
Influenza A Infections In The Hospital Elderly. J. Infect
Dis,1995;172:389-94
-
CDC: http://www.cdc.gov/rsv/research/us-surveillance.html
- Widmer, K. et al. Rates of Hospitalizations for
Respiratory Syncytial Virus, Human Metapneumovirus and Influenza
Virus in Older Adults. J Infect Dis, 2012; 206: 56-62.
- Widmer, K. et al. Respiratory Syncytial Virus & Human
Metapneumovirus-Associated Emergency Department and Hospital
Burden in Adults. Influenza Other Respir Viruses, 2014;
8(3): 347-352.
- Nair, H. et al. Global burden of acute lower
respiratory infections due to respiratory syncytial virus in young
children: a systematic review and meta-analysis. Lancet, 2010;
375: 1545-1555.
- Hall, C.B. et al. Respiratory Syncytial
Virus-Associated hospitalizations Among Children Less Than 24
Months of Age. Pediatrics, 2013; 132(2): E341-348.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
ir@novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024